Alector, Inc. cash flow statement
In fiscal 2025, Alector, Inc.'s operations generated −$184m of cash; it spent $41,000 on capital projects, leaving free cash flow of −$184m.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −18 | 127 | −99 | −167 | 299 | −20 | −184 | −230 | −184 | −158 |
| Depreciation and amortisation | 1 | 1 | 4 | 6 | 6 | 6 | 6 | 5 | 6 | 5 |
| Stock-based pay | 5 | 7 | 16 | 31 | 41 | 46 | 43 | 39 | 27 | 17 |
| Capital spending | 1 | 2 | 15 | 5 | 3 | 4 | 2 | 1 | 0 | 0 |
| Free cash flow | −19 | 126 | −115 | −172 | 295 | −24 | −187 | −231 | −184 | −158 |
| Free cash flow after stock pay | −24 | 119 | −131 | −202 | 255 | −71 | −229 | −271 | −211 | −175 |
| Shares issued | — | — | — | — | — | — | — | 71 | 20 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −51 | −55 | −61 | −49 | −33 | −42 | −50 | −34 |
| Depreciation and amortisation | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Stock-based pay | 9 | 10 | 8 | 7 | 6 | 5 | 3 | 3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −51 | −55 | −61 | −49 | −33 | −42 | −50 | −34 |
| Free cash flow after stock pay | −60 | −65 | −69 | −56 | −39 | −47 | −53 | −37 |
| Shares issued | — | 0 | — | — | — | 5 | — | — |
Compare with peers
- Lineage Cell Therapeutics, Inc. cash flow
- Keros Therapeutics, Inc. cash flow
- Surrozen, Inc. cash flow
- Mindwalk Holdings Corp. cash flow
- Proqr Therapeutics N.V. cash flow
Head to head: ALEC vs LCTXALEC vs KROSALEC vs SRZN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies